drugset / Trial / NCT05104424

The Study of Quadruple Therapy Intranasal Insulin, Zinc, Gabapentin, Ice Cube Stimulation for Post COVID-19 Smell and Taste Dysfunctions

NCT05104424

Phase 1 Unknown 22 enrolled Ministry of Health, Saudi Arabia
RandomizedParallel-groupOpen-labelTreatment

Summary

post covid-19 smell and taste dysfunction are common globally and affect the quality of life and also have phycological impact and anxiety, also affect on economy as the patients not able to do cooking or buy prepared foods and not eaten, also not able to enter the cooking room and prepare foods for themselves, also the risk of loss of smell the fire accidents because anosmia, many forms of smell dysfunction like anosmia ,hyposmia, and dysosmia ,Phantosmia , parosmia may occurred, the same taste disorders may has many forms like Dysgeusia, phantom taste perception, hypogeusia with dysgeusia. until now no definite treatments for post covid-19 smell and taste disorders , this study is novel study as quadruple therapy Intranasal Insulin, Zinc, Gabapentin, Ice Cube Stimulation may suspect having promising results

Timeline

Start
2021-12-26
Primary completion
2022-08-26
Completion
2022-10-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gabapentin Small molecule 300 mg
Comparator insulin aspart Protein / enzyme biologic 40 iu Intranasal
Comparator Zinc Sulfate Unknown 50 mg Oral